Drugs

Drug Interaction Labeling Guidance

FDA has published a draft guidance, Drug Interaction Information in Human Prescription Drug and Biological Product Labeling, to assist applicants in determining the appropriate placement and content of drug interaction information in labeling as described in the regulations for the content and format of labeling for human prescription drug and biological products. The document says its purpose is to provide recommendations to help ensure that appropriate drug interaction information is consistently placed in the proper sections and subsections within labeling so that the information is clear and accessible to healthcare practitioners and includes content that guides the safe and effective use of the drug.

The guidance does not address methodological considerations for evaluating or interpreting drug interactions during drug development or after drug approval. It includes an Introduction, Background, Content and Format of the Drug Interactions Section, Content Not Included in the Drug Interactions Section, Drug Interaction Content in Other Sections of the Full Prescribing Information, Drug Interaction Content in the Highlights of Prescribing Information, Abbreviations, Definitions, and an Appendix.

Gupta Raises Concerns About Overton’s Independence, Ideology

FDA commissioner nominee Heidi Overton’s responses on vaccines, contraception and abortion medication during her 9/24 Senate confirmation hearing raise concerns that ideology could influence her decision-making if she takes over the agency, MSNBC senior medical analyst Dr. Vin Gupta said Friday. Gupta was particularly critical of Overton’

Overton Confirmation Remains Uncertain After Senate Hearing

FDA commissioner nominee Heidi Overton emerged from her Senate confirmation hearing Thursday (see earlier story) without resolving questions about whether she has enough Republican support to advance — and with a rapidly narrowing window for confirmation before the midterm elections. The Senate Health, Education, Labor and Pensions Committee hearing provided few

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA has classified Boston Scientific's recall of its Imager II Angiographic Catheters as Class I because a manufacturing problem could cause catheter tips to degrade and detach, potentially resulting in life-threatening complications. The agency announced the Class I classification 9/25, updating an Early Alert it issued

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome

FDA has approved Roche’s Gazyva (obinutuzumab) for reducing the risk of relapse in adults and children aged 2 and older with frequently relapsing or steroid-dependent, childhood-onset idiopathic nephrotic syndrome who are in remission. The expanded approval covers the use of the CD20-directed antibody beyond its existing

Read more

Gupta Raises Concerns About Overton’s Independence, Ideology

Overton Confirmation Remains Uncertain After Senate Hearing

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome